Invest in the Future of UK Medicinal CBD

On 1 November 2018 the law changed to allow doctors on the General Medical Council's Specialist Register to prescribe unlicensed cannabinoid-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Medicaleaf's™ vision is to be Europe's leading provider of health and wellness cannabidiol innovations. We are seeking investment to fund product manufacturing and distribution. LEARN MORE

Why Invest We will have a UK Network of ‘Best Practice' medical centres where specialists can prescribe or oversee prescriptions of Medicinal Cannabinoids. Medicaleaf™ intends to generate revenue in excess of £5.34 million in this first trading year. Annual predicted net profit over sales metric of ‘plus 43%'. Medicaleaf™ is aiming for a ‘post-raise' valuation of £20 million with expectations to reach a pre-floatation valuation of £200 million in three years' time. Offset over 50% of your investment with CGT and EIS relief. Minimum Investment £10,000.

CLICK HERE TO FIND OUT MORE

Medicinal Cannabinoids are available if: Your child has one of the rare forms of epilepsy that might be helped by medical Cannabinoids. You have spasticity from MS and treatments for this aren't helping. You are vomiting or feel sick from chemotherapy.

DOWNLOAD YOUR INVESTMENT MEMORANDUM

Disclaimer: The information provided on this email is for information purposes only. The email and its content are not, and should not be deemed to be an invitation to engage in any financial activity. The email should not be construed as advice, or a personal recommendation. We are not authorised and regulated by the Financial Conduct Authority (FCA). The content of this email is not authorised under the Financial Services and Markets Act 2000 (FSMA). Reliance on this email for the purpose of engaging in any financial activity may expose an individual to a significant risk of losing all of the funds. UK residents wishing to participate in must fall into the category of sophisticated investor or high net worth individual as outlined by the Financial Conduct Authority (FCA).